ArticleInternational journal of breast cancer2013
Utilization of Oncotype DX in an Inner City Population: Race or Place?
Article in International journal of breast cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00233077 (Patient Assistance to Reduce Breast Cancer Disparities), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Patient Assistance to Reduce Breast Cancer Disparities
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.NPJ breast cancer · 2024Article
- Article
- Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.Breast cancer research and treatment · 2023Article
- Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer.Cancer medicine · 2023Article
- Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age.Breast cancer research and treatment · 2022Article
- A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©.Journal of personalized medicine · 2022Article
- The Role of Medical Mistrust in Concerns about Tumor Genomic Profiling among Black and African American Cancer Patients.International journal of environmental research and public health · 2022Article
- Supervised machine learning model to predict oncotype DX risk category in patients over age 50.Breast cancer research and treatment · 2022Article
- Identifying Clinicopathological Factors Associated with Oncotype DXJournal of personalized medicine · 2021Article
- Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.Breast cancer research and treatment · 2017Article
- Low utility of Oncotype DX® in the clinic.Cancer medicine · 2017Article
- Estimating the OncotypeDX score: validation of an inexpensive estimation tool.Breast cancer research and treatment · 2017Article
- Implementation of the 21-gene recurrence score test in the United States in 2011.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Article
- Underutilization of gene expression profiling for early-stage breast cancer in California.Cancer causes & control : CCC · 2016Article
- Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Breast cancer research and treatment · 2016Article
- Breast cancer multigene testing trends and impact on chemotherapy use.The American journal of managed care · 2016Article
- Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).Journal of the National Cancer Institute · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Oncotype DX, a 21-gene-array analysis, can guide chemotherapy treatment decisions for women with ER+ tumors. Of 225 ER+ women participating in a patient assistance trial, 23% underwent Oncotype DX testing: 31% of whites, 21% of blacks, and 14% of Hispanics (P = 0.04) were tested. Only 3 white women were treated at municipal hospitals and none was tested. 3% of women treated in municipal hospital as compared to 30% treated at tertiary referral centers were tested (P = 0.001). Within tertiary referral centers, there was no racial difference in testing: 32% of whites, 29% of blacks, and 19% of Hispanics (P = 0.25). Multivariate analysis (model c-statistic = 0.76; P < 0.0001) revealed that women who underwent testing were more likely to have stage 1B (RR = 1.70; 95% CI: 1.45-1.85) and to be treated after 2007 (RR = 1.34; 95% CI: 1.01-1.65) and less likely to be treated at a municipal hospital (RR = 0.20; 95% CI: 0.04-0.94). Women treated at municipal hospitals were less likely to undergo testing resulting in a misleading racial disparity that is driven by site of care. As Oncotype DX can reduce overuse of chemotherapy, it is imperative to expand testing to those who could benefit from yet experience underuse of this test, namely, women treated at safety net hospitals. This trial is registered with NCT00233077.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.